1[1]Souko M. A comparison of two dose levels of granisetron in patients receiving high dose cisplatin[J]. Eur J Cancer, 1990,26(suppl 1):15-19.
2[2]Tabona MV. An overview of the use of granisetron in the treatment of emesis associated with cytostatic chemotherapy[J].Eur J Cancer ,1990;24(suppl):s37-41.
3[3]Plosker GL,Goa KL. Granisetron. A review of its pharmacological properties and therapeutic use as antiemetic[J]. Drugs,1991,42(5):805-824.
4[4]Marty M. A comparative stydy of the use of granisetron, a selective 5-HT3 antigonist,versus a standard antiemetic regimen of chlorpromzine plus dexamethasone in the treatment of cytostatic induced emesis[J]. Eur J Cancer,1990,26(suppl):s20-32.
5[5]Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with Granisetron in the prophylaxis of ciplatin- induced aculte emesis: A multicentre, double-blind,randomised, paraller-group study[J].Oncology,1994,51(1):113-118.
7U.S. National Cancer Institute. CTEP, NCI guidelines: adverse e- vent reporting requirements[ R]. Effective: cancer therapy evaluation program, 2005.
8周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,1997:331-332.
9Navari RM. Casopitant, a neurokinin - 1 receptor antagonist with anti - emetic and anti - nausea activities [ J ]. Curr Opin Investig Drugs, 2008,9 ( 7 ) : 774 - 785.
10Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclo- pramide for the treatment of breakthrough chemotherapy - induced nausea and vomiting in patients receiving highly emetogenic chemo- therapy [J]. Support Care Cancer,2013,21 (6) :1655 - 1663.
